Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Progyny Inc (NASDAQ: PGNY) closed at $31.88 in the last session, down -2.66% from day before closing price of $32.75. In other words, the price has decreased by -$2.66 from its previous closing price. On the day, 1.3 million shares were traded. PGNY stock price reached its highest trading level at $33.5 during the session, while it also had its lowest trading level at $31.8.
Ratios:
We take a closer look at PGNY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.61. For the most recent quarter (mrq), Quick Ratio is recorded 3.44 and its Current Ratio is at 3.44. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $49.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $48.
On September 27, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $46.Canaccord Genuity initiated its Buy rating on September 27, 2023, with a $46 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 23 ’24 when Payson Norman sold 200 shares for $56.29 per share. The transaction valued at 11,258 led to the insider holds 580,656 shares of the business.
Livingston Mark S. sold 11,165 shares of PGNY for $419,979 on Apr 01 ’24. The CHIEF FINANCIAL OFFICER now owns 50,119 shares after completing the transaction at $37.62 per share. On Apr 01 ’24, another insider, Sturmer Michael E, who serves as the PRESIDENT of the company, sold 6,395 shares for $37.60 each. As a result, the insider received 240,452 and left with 384,553 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 3063996416 and an Enterprise Value of 2724704000. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.69, and their Forward P/E ratio for the next fiscal year is 32.09. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.67. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.83 while its Price-to-Book (P/B) ratio in mrq is 5.51. Its current Enterprise Value per Revenue stands at 2.503 whereas that against EBITDA is 42.266.
Stock Price History:
Over the past 52 weeks, PGNY has reached a high of $44.95, while it has fallen to a 52-week low of $29.44. The 50-Day Moving Average of the stock is -13.89%, while the 200-Day Moving Average is calculated to be -12.11%.
Shares Statistics:
According to the various share statistics, PGNY traded on average about 808.62K shares per day over the past 3-months and 616220 shares per day over the past 10 days. A total of 95.73M shares are outstanding, with a floating share count of 83.09M. Insiders hold about 13.90% of the company’s shares, while institutions hold 87.13% stake in the company. Shares short for PGNY as of 1711584000 were 6533094 with a Short Ratio of 8.08, compared to 1709164800 on 6483232. Therefore, it implies a Short% of Shares Outstanding of 6533094 and a Short% of Float of 8.2399994.
Earnings Estimates
The market rating for Progyny Inc (PGNY) is a result of the insights provided by Polestar Automotive Holding UK analysts actively involved in the assessment.The consensus estimate for the next quarter is $9.79, with high estimates of $2.28 and low estimates of $31.88.
Analysts are recommending an EPS of between $Consumer Defensive and $Healthcare for the fiscal current year, implying an average EPS of $Technology.
